Clinical Trials
11 trialsNCT04188405 2026-06-05
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT03690115 2025-03-25
PONALLO
Versailles Hospital
Phase 2 Completed
NCT02272998 2025-03-24
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01935336 2022-02-11
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
University of Colorado, Denver
Phase 2 Completed
NCT01641107 2021-11-30
LAL1811
Incyte Corporation
Phase 2 Completed
NCT01207440 2021-02-02
PACE
Takeda
Phase 2 Completed
NCT02265341 2020-11-25
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Mayo Clinic
Phase 2 Completed
NCT01813734 2019-12-24
Ponatinib in Advanced NSCLC w/ RET Translocations
Massachusetts General Hospital
Phase 2 Completed
NCT02478164 2018-07-24
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01874665 2018-05-18
GIST
Takeda
Phase 2 Completed